Cardiovascular  ||| S:0 E:15 ||| NNP
and  ||| S:15 E:19 ||| CC
renal  ||| S:19 E:25 ||| JJ
effects  ||| S:25 E:33 ||| NNS
of  ||| S:33 E:36 ||| IN
chronic  ||| S:36 E:44 ||| JJ
exposure  ||| S:44 E:53 ||| NN
to  ||| S:53 E:56 ||| TO
high  ||| S:56 E:61 ||| JJ
altitude  ||| S:61 E:70 ||| NN
Over  ||| S:70 E:75 ||| IN
140  ||| S:75 E:79 ||| CD
million  ||| S:79 E:87 ||| CD
people  ||| S:87 E:94 ||| NNS
live  ||| S:94 E:99 ||| VBP
at  ||| S:99 E:102 ||| IN
high  ||| S:102 E:107 ||| JJ
altitude ||| S:107 E:115 ||| NN
,  ||| S:115 E:117 ||| ,
defined  ||| S:117 E:125 ||| VBN
as  ||| S:125 E:128 ||| IN
living  ||| S:128 E:135 ||| VBG
at  ||| S:135 E:138 ||| IN
an  ||| S:138 E:141 ||| DT
altitude  ||| S:141 E:150 ||| NN
of  ||| S:150 E:153 ||| IN
2400  ||| S:153 E:158 ||| CD
m  ||| S:158 E:160 ||| NNS
or  ||| S:160 E:163 ||| CC
more  ||| S:163 E:168 ||| JJR
above  ||| S:168 E:174 ||| IN
sea  ||| S:174 E:178 ||| NN
level ||| S:178 E:183 ||| NN
.  ||| S:183 E:185 ||| .
Subjects  ||| S:185 E:194 ||| NNS
living  ||| S:194 E:201 ||| VBG
under  ||| S:201 E:207 ||| IN
these  ||| S:207 E:213 ||| DT
conditions  ||| S:213 E:224 ||| NNS
are  ||| S:224 E:228 ||| VBP
continuously  ||| S:228 E:241 ||| RB
living  ||| S:241 E:248 ||| VBG
under  ||| S:248 E:254 ||| IN
hypoxic  ||| S:254 E:262 ||| JJ
conditions  ||| S:262 E:273 ||| NNS
and ||| S:273 E:276 ||| CC
,  ||| S:276 E:278 ||| ,
depending  ||| S:278 E:288 ||| VBG
on  ||| S:288 E:291 ||| IN
the  ||| S:291 E:295 ||| DT
population ||| S:295 E:305 ||| NN
,  ||| S:305 E:307 ||| ,
various  ||| S:307 E:315 ||| JJ
adaptations  ||| S:315 E:327 ||| NNS
have  ||| S:327 E:332 ||| VBP
developed ||| S:332 E:341 ||| VBN
.  ||| S:341 E:343 ||| .
Interestingly ||| S:343 E:356 ||| RB
,  ||| S:356 E:358 ||| ,
subjects  ||| S:358 E:367 ||| NNS
living  ||| S:367 E:374 ||| VBG
chronically  ||| S:374 E:386 ||| RB
at  ||| S:386 E:389 ||| IN
high  ||| S:389 E:394 ||| JJ
altitude  ||| S:394 E:403 ||| NNS
appear  ||| S:403 E:410 ||| VBP
to  ||| S:410 E:413 ||| TO
have  ||| S:413 E:418 ||| VB
a  ||| S:418 E:420 ||| DT
decreased  ||| S:420 E:430 ||| JJ
frequency  ||| S:430 E:440 ||| NN
of  ||| S:440 E:443 ||| IN
obesity ||| S:443 E:450 ||| NN
,  ||| S:450 E:452 ||| ,
diabetes  ||| S:452 E:461 ||| NN
and  ||| S:461 E:465 ||| CC
coronary  ||| S:465 E:474 ||| JJ
artery  ||| S:474 E:481 ||| NN
disease ||| S:481 E:488 ||| NN
.  ||| S:488 E:490 ||| .
However ||| S:490 E:497 ||| RB
,  ||| S:497 E:499 ||| ,
these  ||| S:499 E:505 ||| DT
benefits  ||| S:505 E:514 ||| NNS
on  ||| S:514 E:517 ||| IN
health  ||| S:517 E:524 ||| NN
are  ||| S:524 E:528 ||| VBP
balanced  ||| S:528 E:537 ||| VBN
by  ||| S:537 E:540 ||| IN
the  ||| S:540 E:544 ||| DT
frequent  ||| S:544 E:553 ||| JJ
development  ||| S:553 E:565 ||| NN
of  ||| S:565 E:568 ||| IN
systemic  ||| S:568 E:577 ||| JJ
and  ||| S:577 E:581 ||| CC
pulmonary  ||| S:581 E:591 ||| JJ
hypertension ||| S:591 E:603 ||| NN
.  ||| S:603 E:605 ||| .
Recently ||| S:605 E:613 ||| RB
,  ||| S:613 E:615 ||| ,
it  ||| S:615 E:618 ||| PRP
has  ||| S:618 E:622 ||| VBZ
been  ||| S:622 E:627 ||| VBN
recognized  ||| S:627 E:638 ||| VBN
that  ||| S:638 E:643 ||| IN
subjects  ||| S:643 E:652 ||| NNS
living  ||| S:652 E:659 ||| VBG
at  ||| S:659 E:662 ||| IN
high  ||| S:662 E:667 ||| JJ
altitude  ||| S:667 E:676 ||| NNS
are  ||| S:676 E:680 ||| VBP
at  ||| S:680 E:683 ||| IN
risk  ||| S:683 E:688 ||| NN
for  ||| S:688 E:692 ||| IN
developing  ||| S:692 E:703 ||| VBG
high-altitude  ||| S:703 E:717 ||| JJ
renal  ||| S:717 E:723 ||| JJ
syndrome  ||| S:723 E:732 ||| NN
( ||| S:732 E:733 ||| -LRB-
HARS ||| S:733 E:737 ||| NNP
) ||| S:737 E:738 ||| -RRB-
,  ||| S:738 E:740 ||| ,
which  ||| S:740 E:746 ||| WDT
is  ||| S:746 E:749 ||| VBZ
a  ||| S:749 E:751 ||| DT
syndrome  ||| S:751 E:760 ||| NN
consisting  ||| S:760 E:771 ||| VBG
of  ||| S:771 E:774 ||| IN
polycythemia ||| S:774 E:786 ||| NN
,  ||| S:786 E:788 ||| ,
hyperuricemia ||| S:788 E:801 ||| NN
,  ||| S:801 E:803 ||| ,
systemic  ||| S:803 E:812 ||| JJ
hypertension  ||| S:812 E:825 ||| NN
and  ||| S:825 E:829 ||| CC
microalbuminuria ||| S:829 E:845 ||| NN
,  ||| S:845 E:847 ||| ,
but  ||| S:847 E:851 ||| CC
with  ||| S:851 E:856 ||| IN
preserved  ||| S:856 E:866 ||| JJ
glomerular  ||| S:866 E:877 ||| JJ
filtration  ||| S:877 E:888 ||| JJ
rate ||| S:888 E:892 ||| NN
.  ||| S:892 E:894 ||| .
More  ||| S:894 E:899 ||| JJR
studies  ||| S:899 E:907 ||| NNS
should  ||| S:907 E:914 ||| MD
be  ||| S:914 E:917 ||| VB
performed  ||| S:917 E:927 ||| VBN
to  ||| S:927 E:930 ||| TO
characterize  ||| S:930 E:943 ||| VB
the  ||| S:943 E:947 ||| DT
mechanisms  ||| S:947 E:958 ||| NNS
and  ||| S:958 E:962 ||| CC
etiology  ||| S:962 E:971 ||| NN
of  ||| S:971 E:974 ||| IN
HARS ||| S:974 E:978 ||| NNP
;  ||| S:978 E:980 ||| :
as  ||| S:980 E:983 ||| IN
such  ||| S:983 E:988 ||| JJ
studies  ||| S:988 E:996 ||| NNS
may  ||| S:996 E:1000 ||| MD
be  ||| S:1000 E:1003 ||| VB
of  ||| S:1003 E:1006 ||| IN
benefit  ||| S:1006 E:1014 ||| NN
not  ||| S:1014 E:1018 ||| RB
only  ||| S:1018 E:1023 ||| RB
to  ||| S:1023 E:1026 ||| TO
the  ||| S:1026 E:1030 ||| DT
high-altitude  ||| S:1030 E:1044 ||| JJ
population ||| S:1044 E:1054 ||| NN
,  ||| S:1054 E:1056 ||| ,
but  ||| S:1056 E:1060 ||| CC
also  ||| S:1060 E:1065 ||| RB
to  ||| S:1065 E:1068 ||| TO
better  ||| S:1068 E:1075 ||| JJR
understanding  ||| S:1075 E:1089 ||| NN
of  ||| S:1089 E:1092 ||| IN
the  ||| S:1092 E:1096 ||| DT
renal  ||| S:1096 E:1102 ||| JJ
consequences  ||| S:1102 E:1115 ||| NNS
of  ||| S:1115 E:1118 ||| IN
acute  ||| S:1118 E:1124 ||| JJ
and  ||| S:1124 E:1128 ||| CC
chronic  ||| S:1128 E:1136 ||| JJ
hypoxia ||| S:1136 E:1143 ||| NN
.  ||| S:1143 E:1145 ||| .
